TY - JOUR
T1 - Rituximab and pregnancy
T2 - Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth
AU - Gonzalez Caldito, Natalia
AU - Graham, Edith L.
AU - Grebenciucova, Elena
N1 - Publisher Copyright:
© The Author(s), 2023.
PY - 2024/2
Y1 - 2024/2
N2 - Late-onset neutropenia (LON) is a rare adverse event that has not been reported from in utero exposure. We describe a case of LON in an infant, whose mother had neuromyelitis optica and received rituximab in the third trimester due to re-emergence of CD19 B cells. The newborn was born without complications but 2 months later was found to have grade IV neutropenia. No etiology was identified. Neutropenia self-resolved within 1 week. This case emphasizes an unmet need for developing guidelines and protocols to manage in utero rituximab exposure.
AB - Late-onset neutropenia (LON) is a rare adverse event that has not been reported from in utero exposure. We describe a case of LON in an infant, whose mother had neuromyelitis optica and received rituximab in the third trimester due to re-emergence of CD19 B cells. The newborn was born without complications but 2 months later was found to have grade IV neutropenia. No etiology was identified. Neutropenia self-resolved within 1 week. This case emphasizes an unmet need for developing guidelines and protocols to manage in utero rituximab exposure.
KW - CD20 monoclonal antibody
KW - Rituximab
KW - delayed-onset neutropenia
KW - neuromyelitis optica spectrum disorder
KW - pregnancy
KW - side effects
UR - http://www.scopus.com/inward/record.url?scp=85177648334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177648334&partnerID=8YFLogxK
U2 - 10.1177/13524585231214219
DO - 10.1177/13524585231214219
M3 - Article
C2 - 38116592
AN - SCOPUS:85177648334
SN - 1352-4585
VL - 30
SP - 272
EP - 274
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 2
ER -